Search

PURPOSE: Amyands hernia is a rare hernia defined as an inguinal hernia that contains the appendix within the hernia sac. Current treatment of Amyands hernia remains controversial. Our study retrospectively reviewed 6 cases of Amyands hernia, aiming to provide a reference for the surgical treatment of Amyands hernia. METHODS: Six patients diagnosed with Amyands hernia from September 2010 to May 2020 were retrospectively enrolled in our study. We summarized clinical data of six patients including the chief complaint, physical examinations, laboratory examinations, imaging examinations, surgical methods, and postoperative treatments and outcomes. RESULTS: The diagnosis of six cases with Amyands hernia was made during surgery. Two patients had normal appendixes whereas the remaining four patients had appendicitis. Two patients with normal appendix received tension-free mesh repair through the inguinal incision. Among those with inflamed or perforated appendixes, two received mesh repair and the other two did not. The discharge time after surgery of six patients was 9.8 ± 6.1 days. One patient suffered from a wound infection. No additional postoperative complications were detected. CONCLUSIONS: Computed tomography and ultrasonography are helpful but limited in the definite diagnosis of Amyands hernia. The presence of a normal appendix does not require to be resected, but appendicectomy is necessary if the appendix is inflamed. The treatment of Amyands hernia should be tailored based on the patients condition and the type of Amyands hernia.

A coffee-certified reference material (CRM) for ochratoxin A, B, and C (OTA, OTB, and OTC) was created to improve the precision and reliability of these toxins. A collection of 100 bottles (each containing 10 g) of the CRM candidate for OTA, OTB, and OTC was produced by applying a mixed standard solution of OTA, OTB, and OTC to moderately roasted beans that subsequently ground and homogenized. Moreover, considering the intricate matrix interference in coffee, a rapid and sensitive method for OTA, OTB, and OTC in coffee was developed with minimal matrix effects. This approach employed liquid chromatography–tandem mass spectrometry and mixed purification materials (C18 and hydroxylated multi-walled carbon nanotubes (MWCNTs), OH-MWCNTs) for the analysis. Based on the standards GB/T 15000.3-2008/ISO Guide 35: 2017, the CRM demonstrated robust uniformity and stability when stored for 14 d at 4, 20, and 40 °C, and 12 months at −20 °C. Eight laboratories were employed to characterize the CRM. The certified values for OTA, OTB, and OTC in coffee were established to be 15.2 ± 0.4, 12.8 ± 0.4, and 3.4 ± 0.1 μg/kg (with a coverage factor k = 2, representing an approximate 95% confidence interval). [ABSTRACT FROM AUTHOR]

SWATHtoMRM technology was used in this experiment to further identify and trace the sources of Dendrobium devonianum and Dendrobium officinale produced in the same area using TOF and MS-MRM. After the conversion of the R package of SWATHtoMRM, 191 MRM pairs of positive ions and 96 pairs of negative ions were obtained. Dendrobium devonianum and Dendrobium officinale can be separated very well using the PCA and PLS-DA analysis of MRM ion pairs; this shows that there are obvious differences in chemical composition between Dendrobium devonianum and Dendrobium officinale, which clearly proves that the pseudotargeted metabolomics method based on SWATHtoMRM can be used for traceability identification research. A total of 146 characteristic compounds were obtained, with 20 characteristic compounds in Dendrobium devonianum. The enrichment pathways of the characteristic compounds were mainly concentrated in lipids and atherosclerosis, chagas disease, fluid shear stress and atherosclerosis, proteoglycans in cancer, the IL-17 signaling pathway, the sphingolipid signaling pathway, diabetic cardiomyopathy, arginine and proline metabolism, etc., among which the lipid and atherosclerosis pathways were more enriched, and 11 characteristic compounds affected the expression levels of IL-1, TNFα, CD36, IL-1β, etc. These can be used as a reference for research on variety improvement and active substance accumulation in Dendrobium devonianum and Dendrobium officinale. [ABSTRACT FROM AUTHOR]

Background: The efficacy and safety of anti-nerve growth factor (NGF) antibody therapy used for osteoarthritis (OA) pain are controversial., Purpose: To evaluate the efficacy and safety of anti-NGF antibody therapy via a meta-analysis of randomized controlled trials (RCTs)., Study Design: Systematic review; Level of evidence, 1., Methods: PubMed, the Cochrane Central Register of Controlled Trials, Embase, and the Web of Science databases were searched for RCTs assessing anti-NGF antibody treatments for hip and knee OA. A total of 623 records were retrieved from the databases. A random-effects model was used to assess primary and secondary outcomes. Bias was assessed using the Cochrane Collaboration tool, funnel plots, and the Egger test. Subgroup analyses were used to assess the efficacy and safety of the independent variables. Sensitivity analysis was conducted to evaluate the effectiveness of tanezumab and the effectiveness of anti-NGF antibodies compared to active comparator drugs. We present the effects of dose, administration mode, and treatment duration on the efficacy and safety of anti-NGF antibody therapy., Results: There were 19 RCTs included in our meta-analysis. Anti-NGF antibody treatment showed significant improvements on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) for pain, physical function, and stiffness as well as on a patient global assessment (PGA). The overall standardized mean differences were as follows: WOMAC pain (-0.31 [95% CI, -0.36 to -0.26]; Z  = 11.75; P  < .001; I 2 = 38%), WOMAC physical function (-0.36 [95% CI, -0.41 to -0.30]; Z = 12.67; P < .001; I 2 = 44%), WOMAC stiffness (-3.59 [95% CI, -4.87 to -2.30]; Z = 5.47; P < .001; I 2 = 98%), and PGA (-0.28 [95% CI, -0.34 to -0.22]; Z = 9.39; P < .001; I 2 = 50%). Anti-NGF antibody treatment resulted in a greater incidence of adverse events (risk ratio, 1.09 [95% CI, 1.06 to 1.12]; Z  = 5.60; P < .001; I 2 = 0%). The incidence of serious adverse events was similar between the treatment and control groups (risk ratio, 1.15 [95% CI, 0.98 to 1.34]; Z  = 1.71; P = .09; I 2 = 0%)., Conclusion: Anti-NGF antibody treatment significantly relieved pain and improved function in patients with hip and knee OA. However, no conclusion could be drawn regarding the optimal treatment plan for anti-NGF antibodies when all 3 variables (dose, administration mode, and treatment duration) were combined in the analyses., Competing Interests: The authors have declared that there are no conflicts of interest in the authorship and publication of this contribution. AOSSM checks author disclosures against the Open Payments Database (OPD). AOSSM has not conducted an independent investigation on the OPD and disclaims any liability or responsibility relating thereto., (© The Author(s) 2022.)